Researchers at Johns Hopkins have published results from a trial of a one-shot opiod-addiction drug that lasts for six weeks and prevents widthrawal symptoms.
Five opioid-dependent volunteers each received a single subcutaneous depot injection containing 58 mg of buprenorphine and were assessed for at least four weeks for signs and symptoms of opioid withdrawal, first residentially and then as outpatients. Depot buprenorphine appeared to provide effective relief from opioid withdrawal, with no participant requiring additional medication for withdrawal relief following depot administration.
(via Ambiguous)
